On October 12, Panson issued an announcement announcing that it had officially signed a privatization merger agreement, corresponding to the valuation of the Pan-son transaction of about $126 million.

Under the agreement, Panson will merge with the parent company (New Genetron Holding Limited), and Panson will continue as a surviving entity and become a wholly-owned subsidiary of the parent company. The buyer group participating in the transaction includes CICC Concord Medical Fund, Wealth Strategy Holding Limited, Wuxi Guolian Group, CCB (Beijing) Investment Fund Management Co., LTD., Wuxi Huihong Yingkang Investment Partnership (Limited Partnership), etc.
According to the agreement, the purchase price per ordinary share is $0.272 and the purchase price per American Depositary Share (" ADS ", where each ADS represents five ordinary shares) is $1.36. According to the signed agreement, the transaction price represents a premium of approximately 15% to the last trading day before Panson announced that it had received the privatization offer; The offer represents a 21 per cent premium to the average closing price in the 30 trading days prior to the announcement of the take-private offer. As of October 11, 2023, the last trading day before the announcement, the premium is 42%.
The privatization transaction is expected to be completed in the first quarter of 2024, the announcement said.
Public information shows that Panson is a global cutting-edge precision cancer medicine company, providing early cancer screening, diagnosis and monitoring, drug research and development services covering the full cycle of cancer products and services, comprehensive coverage of China's top ten cancer types, and has "one step method", Mutation Capsule and other original research patented technology. In addition, Panson is the only precision medical enterprise that has entered the national major project of early screening of liver cancer, lung cancer, digestive tract cancer and other cancers of the Ministry of Science and Technology, and its lung cancer precision diagnosis and treatment project won the second prize of National Science and Technology Progress. (Li Gongsheng)